SCHEMBL6364339

SCHEMBL6364339

CC(=O)N1CCN(C(=O)c2cccc(-c3cnc(N)c(OCc4ccccc4C(F)(F)F)c3)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.55
PIK3CD O00329 6/20 0.53
PIK3CA P42336 6/20 0.53
PIK3CB P42338 6/20 0.53
PIK3CG P48736 6/20 0.53
MAP4K3 Q8IVH8 1/20 0.49
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KCNH2 Q12809 2/20 0.45
MAP3K11 Q16584 1/20 0.45
FYN P06241 1/20 0.45
PIK3C3 Q8NEB9 1/20 0.44
MAPT P10636 2/20 0.42
ALOX15 P16050 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NR1H2 P55055 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL488532 0.91 MET (0.65) METPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30453327 0.91 MET (0.65) METPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30453650 0.84 MET (0.65) METMAP4K3KCNH2
SCHEMBL488012 0.84 MET (0.65) METMAP4K3KCNH2
SCHEMBL27915639 0.81 MET (0.61) METMAP4K3ALDH1A1LMNAMEN1
SCHEMBL27915640 0.80 MET (0.60) METMAP4K3ALDH1A1LMNAMEN1
SCHEMBL488146 0.78 MET (0.63) METMAP4K3KCNH2MAP3K11
SCHEMBL30453233 0.78 MET (0.63) METMAP4K3KCNH2MAP3K11
SCHEMBL30453248 0.78 MET (0.69) METMAP4K3
SCHEMBL487635 0.78 MET (0.69) METMAP4K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer MET, ERBB2, CDK4 MET 1/4885PIK3CD 648/4885PIK3CA 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.